Search results

709 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
NICE guidelines Remove NICE guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter
Public health guidelines Remove Public health guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]

In development [GID-TA10596] Expected publication date: 15 December 2021

Type

Technology appraisal guidance

Status

In development
Antenatal care

In development [GID-NG10096] Expected publication date: 11 August 2021

Type

NICE guideline

Status

In development
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]

In development [GID-TA10729] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]

In development [GID-TA10481] Expected publication date: 18 August 2021

Type

Technology appraisal guidance

Status

In development
Head injury: assessment and early management

In development [GID-NG10164] Expected publication date: 11 May 2022

Type

NICE guideline

Status

In development
Shared decision making

In development [GID-NG10120] Expected publication date: 17 June 2021

Type

NICE guideline

Status

In development
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]

In development [GID-TA10806] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ectopic pregnancy and miscarriage: diagnosis and initial management (update)

In development [GID-NG10173] Expected publication date: TBC

Type

NICE guideline

Status

In development
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]

In development [GID-TA10705] Expected publication date: 17 November 2021

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - lubiprostone [ID646]

In development [GID-TAG367] Expected publication date: 01 October 2014

Type

Technology appraisal guidance

Status

In development
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]

Proposed [GID-TA10600] Expected publication date: 22 December 2021

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]

In development [GID-TA10417] Expected publication date: 15 September 2021

Type

Technology appraisal guidance

Status

In development
Nitisinone for treating alkaptonuria [ID2691]

Proposed [GID-TA10659] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Hypertension in adults: diagnosis and management (update)

In development [GID-NG10177] Expected publication date: 19 April 2023

Type

NICE guideline

Status

In development
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma [ID3862]

In development [GID-TA10744] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]

In development [GID-TA10725] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]

In development [GID-TA10742] Expected publication date: 05 January 2022

Type

Technology appraisal guidance

Status

In development
Abiraterone for treating newly diagnosed high risk metastatic hormone-naive prostate cancer [ID945]

In development [GID-TA10122] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]

In development [GID-TA10613] Expected publication date: 13 October 2021

Type

Technology appraisal guidance

Status

In development
PredictSURE IBD and IBDX to guide treatment of Crohn's disease

In development [GID-DG10029] Expected publication date: TBC

Type

Diagnostics guidance

Status

In development
Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management

In development [GID-NG10149] Expected publication date: 08 June 2022

Type

NICE guideline

Status

In development
Clostridioides difficile infection: antimicrobial prescribing

In development [GID-NG10144] Expected publication date: 23 July 2021

Type

Antimicrobial prescribing guideline

Status

In development
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF Review of TA558) [ID1681]

In development [GID-TA10644] Expected publication date: 17 March 2021

Type

Technology appraisal guidance

Status

In development
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]

Proposed [GID-TA10802] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]

Proposed [GID-TA10803] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]

Proposed [GID-TA10804] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Melanoma: assessment and management

In development [GID-NG10155] Expected publication date: 06 July 2022

Type

NICE guideline

Status

In development
Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

In development [GID-TA10558] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]

Proposed [GID-TA10791] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Mitapivat for treating pyruvate kinase deficiency [ID3914 ]

Proposed [GID-TA10795] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]

Proposed [GID-TA10792] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Tezepelumab for maintenance treatment of uncontrolled severe asthma in people aged 12 and over [ID3910]

Proposed [GID-TA10796] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Difelikefalin for treating pruritis in people having haemodialysis [ID3890 ]

Proposed [GID-TA10793] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]

Proposed [GID-TA10797] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Brolucizumab for treating diabetic macular oedema [ID3902]

Proposed [GID-TA10794] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating diabetic macular oedema [ID3899]

Proposed [GID-TA10798] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Faricimab for treating wet age-related macular degeneration [ID3898 ]

Proposed [GID-TA10799] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

Proposed [GID-TA10800] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]

Proposed [GID-TA10801] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Stroke rehabilitation in adults

In development [GID-NG10175] Expected publication date: 14 December 2022

Type

NICE guideline

Status

In development
Chronic kidney disease: assessment and management (update)

In development [GID-NG10118] Expected publication date: 20 July 2021

Type

NICE guideline

Status

In development
Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]

In development [GID-TA10611] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Bulevirtide for treating chronic hepatitis D [ID3732]

In development [GID-TA10652] Expected publication date: 20 October 2021

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]

In development [GID-TA10538] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Non-bisphosphonates for treating osteoporosis [ID901]

In development [GID-TA10072] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]

In development [GID-TA10701] Expected publication date: 20 July 2022

Type

Technology appraisal guidance

Status

In development
Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]

In development [GID-TA10669] Expected publication date: 04 May 2022

Type

Technology appraisal guidance

Status

In development
Chronic pain: assessment and management

In development [GID-NG10069] Expected publication date: 07 April 2021

Type

NICE guideline

Status

In development
Ofatumumab for treating relapsing multiple sclerosis [ID1677]

In development [GID-TA10557] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development